COYA
Coya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.20
−1.18%Oct 14, 2026, 12:00 UTC
Coya Therapeutics announced plans to initiate an open-label extension of its Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis, in response to requests from trial investigators.
Source:Aug 11, 2026, 12:00 UTC
Coya Therapeutics reported its financial results for the second quarter of 2026 and provided a corporate update.
Source: